Pregabalin augmentation of antidepressants in older patients with comorbid depression and generalized anxiety disorder-an open-label study

Dimitrios Karaiskos, Dimitra Pappa, Elias Tzavellas, Kostas Siarkos, Everina Katirtzoglou, George N. Papadimitriou, Antonis Politis

Research output: Contribution to journalArticle

Abstract

Objective The objective of this 12-week open-label study was to evaluate the efficacy, safety, and tolerability of pregabalin as an adjunctive treatment to antidepressants in older patients suffering from depression and comorbid generalized anxiety disorder (GAD). Methods The initial sample of this open-label study consisted of 94 older patients fulfilling criteria for depression with comorbid GAD who were treated with antidepressants. Twenty of them who had received antidepressant monotherapy for an adequate time and shown partial response to the antidepressant prescribed, in terms of either anxiety or depressive symptomatology, followed the next phase. During the 12-week study period, pregabalin was gradually added to the previously prescribed antidepressant, reaching 225 mg/day over 4 weeks. Depression and anxiety scores as well as side effects were monitored. Within groups, differences of depression and anxiety scores at baseline and during the following 12 weeks of treatment were estimated with repeated-measure analysis of variance. Results A statistical significant reduction in depression scores was observed after the 4th week of treatment (p <0.01), which further improved between the 8th and 12th weeks (p <0.01). Concerning overall anxiety scores, a statistically significant improvement was noted between the 2nd and 4th weeks (p <0.01), which further continued throughout the 8th (p <0.05) and 12th weeks (p <0.05). Conclusions The present study demonstrated a good therapeutic response to pregabalin in patients with depression comorbid with GAD after a 12-week treatment period. Both anxiety and depressive symptomatology significantly improved, and minimal side effects were observed.

Original languageEnglish (US)
Pages (from-to)100-105
Number of pages6
JournalInternational Journal of Geriatric Psychiatry
Volume28
Issue number1
DOIs
StatePublished - Jan 2013
Externally publishedYes

Fingerprint

Anxiety Disorders
Antidepressive Agents
Depression
Anxiety
Therapeutics
Psychological Stress
Pregabalin
Analysis of Variance
Safety

Keywords

  • adjunctive
  • anxiety
  • depression
  • older patient
  • pregabalin

ASJC Scopus subject areas

  • Geriatrics and Gerontology
  • Psychiatry and Mental health

Cite this

Pregabalin augmentation of antidepressants in older patients with comorbid depression and generalized anxiety disorder-an open-label study. / Karaiskos, Dimitrios; Pappa, Dimitra; Tzavellas, Elias; Siarkos, Kostas; Katirtzoglou, Everina; Papadimitriou, George N.; Politis, Antonis.

In: International Journal of Geriatric Psychiatry, Vol. 28, No. 1, 01.2013, p. 100-105.

Research output: Contribution to journalArticle

Karaiskos, Dimitrios ; Pappa, Dimitra ; Tzavellas, Elias ; Siarkos, Kostas ; Katirtzoglou, Everina ; Papadimitriou, George N. ; Politis, Antonis. / Pregabalin augmentation of antidepressants in older patients with comorbid depression and generalized anxiety disorder-an open-label study. In: International Journal of Geriatric Psychiatry. 2013 ; Vol. 28, No. 1. pp. 100-105.
@article{4344e2fdeb82485a84eb5433e46382a5,
title = "Pregabalin augmentation of antidepressants in older patients with comorbid depression and generalized anxiety disorder-an open-label study",
abstract = "Objective The objective of this 12-week open-label study was to evaluate the efficacy, safety, and tolerability of pregabalin as an adjunctive treatment to antidepressants in older patients suffering from depression and comorbid generalized anxiety disorder (GAD). Methods The initial sample of this open-label study consisted of 94 older patients fulfilling criteria for depression with comorbid GAD who were treated with antidepressants. Twenty of them who had received antidepressant monotherapy for an adequate time and shown partial response to the antidepressant prescribed, in terms of either anxiety or depressive symptomatology, followed the next phase. During the 12-week study period, pregabalin was gradually added to the previously prescribed antidepressant, reaching 225 mg/day over 4 weeks. Depression and anxiety scores as well as side effects were monitored. Within groups, differences of depression and anxiety scores at baseline and during the following 12 weeks of treatment were estimated with repeated-measure analysis of variance. Results A statistical significant reduction in depression scores was observed after the 4th week of treatment (p <0.01), which further improved between the 8th and 12th weeks (p <0.01). Concerning overall anxiety scores, a statistically significant improvement was noted between the 2nd and 4th weeks (p <0.01), which further continued throughout the 8th (p <0.05) and 12th weeks (p <0.05). Conclusions The present study demonstrated a good therapeutic response to pregabalin in patients with depression comorbid with GAD after a 12-week treatment period. Both anxiety and depressive symptomatology significantly improved, and minimal side effects were observed.",
keywords = "adjunctive, anxiety, depression, older patient, pregabalin",
author = "Dimitrios Karaiskos and Dimitra Pappa and Elias Tzavellas and Kostas Siarkos and Everina Katirtzoglou and Papadimitriou, {George N.} and Antonis Politis",
year = "2013",
month = "1",
doi = "10.1002/gps.3800",
language = "English (US)",
volume = "28",
pages = "100--105",
journal = "International Journal of Geriatric Psychiatry",
issn = "0885-6230",
publisher = "John Wiley and Sons Ltd",
number = "1",

}

TY - JOUR

T1 - Pregabalin augmentation of antidepressants in older patients with comorbid depression and generalized anxiety disorder-an open-label study

AU - Karaiskos, Dimitrios

AU - Pappa, Dimitra

AU - Tzavellas, Elias

AU - Siarkos, Kostas

AU - Katirtzoglou, Everina

AU - Papadimitriou, George N.

AU - Politis, Antonis

PY - 2013/1

Y1 - 2013/1

N2 - Objective The objective of this 12-week open-label study was to evaluate the efficacy, safety, and tolerability of pregabalin as an adjunctive treatment to antidepressants in older patients suffering from depression and comorbid generalized anxiety disorder (GAD). Methods The initial sample of this open-label study consisted of 94 older patients fulfilling criteria for depression with comorbid GAD who were treated with antidepressants. Twenty of them who had received antidepressant monotherapy for an adequate time and shown partial response to the antidepressant prescribed, in terms of either anxiety or depressive symptomatology, followed the next phase. During the 12-week study period, pregabalin was gradually added to the previously prescribed antidepressant, reaching 225 mg/day over 4 weeks. Depression and anxiety scores as well as side effects were monitored. Within groups, differences of depression and anxiety scores at baseline and during the following 12 weeks of treatment were estimated with repeated-measure analysis of variance. Results A statistical significant reduction in depression scores was observed after the 4th week of treatment (p <0.01), which further improved between the 8th and 12th weeks (p <0.01). Concerning overall anxiety scores, a statistically significant improvement was noted between the 2nd and 4th weeks (p <0.01), which further continued throughout the 8th (p <0.05) and 12th weeks (p <0.05). Conclusions The present study demonstrated a good therapeutic response to pregabalin in patients with depression comorbid with GAD after a 12-week treatment period. Both anxiety and depressive symptomatology significantly improved, and minimal side effects were observed.

AB - Objective The objective of this 12-week open-label study was to evaluate the efficacy, safety, and tolerability of pregabalin as an adjunctive treatment to antidepressants in older patients suffering from depression and comorbid generalized anxiety disorder (GAD). Methods The initial sample of this open-label study consisted of 94 older patients fulfilling criteria for depression with comorbid GAD who were treated with antidepressants. Twenty of them who had received antidepressant monotherapy for an adequate time and shown partial response to the antidepressant prescribed, in terms of either anxiety or depressive symptomatology, followed the next phase. During the 12-week study period, pregabalin was gradually added to the previously prescribed antidepressant, reaching 225 mg/day over 4 weeks. Depression and anxiety scores as well as side effects were monitored. Within groups, differences of depression and anxiety scores at baseline and during the following 12 weeks of treatment were estimated with repeated-measure analysis of variance. Results A statistical significant reduction in depression scores was observed after the 4th week of treatment (p <0.01), which further improved between the 8th and 12th weeks (p <0.01). Concerning overall anxiety scores, a statistically significant improvement was noted between the 2nd and 4th weeks (p <0.01), which further continued throughout the 8th (p <0.05) and 12th weeks (p <0.05). Conclusions The present study demonstrated a good therapeutic response to pregabalin in patients with depression comorbid with GAD after a 12-week treatment period. Both anxiety and depressive symptomatology significantly improved, and minimal side effects were observed.

KW - adjunctive

KW - anxiety

KW - depression

KW - older patient

KW - pregabalin

UR - http://www.scopus.com/inward/record.url?scp=84870917600&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84870917600&partnerID=8YFLogxK

U2 - 10.1002/gps.3800

DO - 10.1002/gps.3800

M3 - Article

VL - 28

SP - 100

EP - 105

JO - International Journal of Geriatric Psychiatry

JF - International Journal of Geriatric Psychiatry

SN - 0885-6230

IS - 1

ER -